share_log

硕世生物(688399.SH):放弃参股公司元宋生物增资优先认购权

Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH) has given up its priority subscription rights for the capital increase of its associated company YUANSONG BIOLOGICAL.

Gelonghui Finance ·  Aug 14 05:55

On August 14th, Gelonhui announced that Yuansong Biotech is a joint-stock company of Jiangsu Bioperfectus Technologies Co., Ltd., and the company holds 9.0561% of its shares. Due to the needs of its own business development, Yuansong Biotech intends to increase its registered capital by 0.238728 million yuan. This increase is partly subscribed by "Yueneng Investment", "Jingyue Jiuyuan", "Xiaofeng Teng", and "Yuansong Partnership". Among them, the company's related party "Jingyue Jiuyuan" invested 30 million yuan, and "Yuansong Partnership" invested 12 million yuan. Taking into account the overall development plan of the company, Jiangsu Bioperfectus Technologies Co., Ltd. intends to waive its priority subscription right for this capital increase. After the completion of this transaction, the company's equity interest in Yuansong Biotech will be reduced to 7.5809%.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment